Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Those are paper gains. If you don’t sell, it doesn’t count as income and doesn’t impact 2024 or 2023 contributions (can make 2023 contributions up to when file 2023 taxes).
Not a negative wave. Someone was connecting dots that didn’t exist.
The new packaging facility in the near future will add great benefit to the company, just not happening this month for these open positions.
There’s no need to disregard reality.
165 Ludlow address is their corp address, not the new packaging location. It says posted job was posted on 10/14, before the deal on the new site. Not sure what you are looking at, but the link doesn’t infer anything about hiring at the new location.
Can you walk me through the math of how 100M shares are dumped to the market today when only 2.4M in total shares are traded. It’s a little fuzzy for me.
Interesting about the reasoning behind the 180-day exclusivity period. I wasn’t aware of that. Getting the FDA approval and clearing the legal hurdles would be fantastic. I’m still of frame of mind that Intas is 1st in line as they were the first to invalidate Purdue’s patents. Unless FDA has had enough of their quality control shenanigans. I simply think Purdue is suing anyone on the path to potentially take marketshare. Would love to see otherwise. If we get initial exclusivity. the stock will fly. I’m curious how long it took Intas to battle through this and the time expectation for Elite. I am no lawyer.
Let’s do the same comparison this time next year. Hindsight is always 20/20. Let’s see what your foresight looks like.
Might want to check your math. 500-750M is a significant portion of the ER market. Elite is the contract manufacturer so we don’t get the full enchilada either. CNS is a fragmented market. Prasco/Burel will not get half of it. It’s simply not realistic. Prasco API is now dictated by DEA whereas it wasn’t previously with the authorized generic. Need to temper expectations significantly.
It was a done deal and expected. Today’s PR was more of a formality. Good to see the timing of initial shipment. Just nice to see the validation of the relationship moving forward.
Just ER
That is not correct. 50% of profit splits. Look at where we are making most of our profits. It’s not from the profit splits, it’s from the manufacturing side.
We don’t know the financial impact other than it being material or a PR wouldn’t be required. Looks like we wait until Q3 financials on Feb to get the initial glimpse and Q4 10K in June to get full quarter’s look. By then, we’ll have been moved into the new facility with packing/storage expansion.
Time to break out the “This is our year” mug again. You’ll actually need it for 2024.
To be soon followed by generic CNS filing FDA acceptance. Keep the news coming.
To get on NASDAQ if you can’t get there organically. With tailwinds, this could be a sweet move. But it’s a long-term move, not one if you plan on being acquired in a couple years.
I could see 5-10:1 taking place to ensure we are well above $5 threshold. More likely to take place in 2025.
Wow dude. Easy tiger. Hope this does better than your AMC investment you were pumping for months.
Nothing has changed. Universities are always doing pharma research. I think Weezuhl’s insight is interesting in the pharma justification of the global pricing model, which is broken.
Agreed, 100% stupid. That is completely against American innovation train and engine for R&D.
That timing has zero impact right now. Everyone got CRLs. Plus, we were one of many back then as everyone had to do the insufflation study. We are also one of many now. Per last cc, no questions have been asked yet on the opioid filing, but does expect them soon. He did say that he expects approval later in the year. I’m expecting the filing wasn’t soon enough.
Also depends on whether we get first to file for generic oxy. Don’t think so, but that would add some serious fuel to the fire.
Prior to $5 share price being hit organically? Absolutely.
This is why you hear Nasrat say the only way we will do a reverse split is to get to NASDAQ.
Using simple math, 1 billion in revenue with a 30% flow through with an incredibly generous 15 multiple wouldn’t even get you there. Perhaps you’re looking 10 years down the road? I would expect company will be acquired long before then.
$1 won’t cut it without a reverse split. Needs to be higher to list on NASDAQ. You do realize that right?
Sadly, it’s been going on for many years.
They won’t. They were more likely to do so several years back, but balked at the idea. Less likely now.
We’ll see about that.
Follow up from SAP dialogue from couple weeks ago. To confirm SAP has already been implemented, check out wording from job posting:
- Material consumption entries into SAP
- Proficiency in Microsoft Excel and Word, SAP
https://www.salary.com/job/elite-pharmaceuticals-inc/production-clerk/j202301200726291263711?utm_campaign=google_jobs_apply&utm_source=google_jobs_apply&utm_medium=organic
Not sure there is much of a market. We’ve heard time and time again that gov’t and patients aren’t willing to pay a premium. Not sure we can throw out premium product without premium pricing to common generic opioids.
High growth (now finally entering that hockey stick growth phase) + expansion beyond generics. Generics don’t get sexy forward multiples, but maybe Elite will be the first. I’d like to see a move to NASDAQ with analyst coverage to broaden exposure. Likely we will be bought before then.
“If you look at just 2023, January through December, that alone will be way north of $45 million.”
Jan-Mar (Q4): $8.64M
Apr-Jun (Q1): $8.98M
Jul-Sep (Q2): $14.16M
Oct-Dec (Q3): $20M?
With Prasco launch does Elite surpass $20M for Q3 and break a $50M revenue threshold for the calendar year? “Way north” is as technical of a finance term as “squishy”, but I’m eager to see another blowout quarter.
By now, they should have already surpassed last year’s $34M total revenues in the final stretch of Q3 with a month left to go + a whole new quarter.
Let the good times roll. Elite finally brings Christmas joy to all. Solid news coming right around the corner.
It’s purely cash timing at this point.
I disagree with your profit split accounting and overall profitability comments. The income statement includes the profit split in the period it’s incurred as an expense. What doesn’t get paid out simply sits on balance sheet as a liability. The current accounting is correct.
I don’t believe so or I believe it would be noted in the filings. We’d also see dilution from it, which we haven’t.
I didn’t say you were wrong, but just clarifying how they got those shares.
I’d have to research, but other than Nasrat I don’t think any have bought shares on open market.
They have been paid in shares for being on the BOD in lieu of cash payment.
Maybe. GameStop has less than 1/3 O/S that Elite has.
Not in 10Q as nothing has shipped yet. Nasrat mentioned that it will be a material event, but the timing on when it becomes material is the question - upon early shipments or at some point in calendar 2024?
The operating profits will cover all this and more. Once we buy Mikah’s share of IR/XR that only further increases profit dollars and % to sales.